METHAZOLAMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C5H8N4O3S2
Molecular Weight	236.272
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1N=C(S\C1=N\C(C)=O)S(N)(=O)=O

InChI

InChIKey=FLOSMHQXBMRNHR-QPJJXVBHSA-N

InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00703
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/methazolamide.html

Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride. Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Methazolamide is used for treatment of chronic open-angle glaucoma and acute angle-closure glaucoma.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175	Inhibitor 8228	50.0 nM [Ki]
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175	Inhibitor 8228	14.0 nM [Ki]
Carbonic anhydrase IX 37 Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175	Inhibitor 8228	27.0 nM [Ki]
Carbonic anhydrase XII 30 Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23965175	Inhibitor 8228	3.4 nM [Ki]
Carbonic anhydrase VII 36 Target ID: CHEMBL2326 Sources: http://www.drugbank.ca/drugs/DB00703	Inhibitor 8228	2.1 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Glaucoma 57 Sources: https://www.drugs.com/pro/methazolamide.html	Primary		Approved 8360	Methazolamide Approved Use indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. Launch Date 7.4131197E11

C_max

Value	Dose	Analyte	Population
2.5 μg/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
5.1 μg/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
10.7 μg/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1130 μg × min/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:	METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2571 μg × min/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
5418 μg × min/mL DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
14 h DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	steady-state, oral		METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
45% DRUG LABEL https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display	25 mg 2 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		METHAZOLAMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/718513	unhealthy, 67.5 years n = 24 Health Status: unhealthy Condition: Glaucoma Age Group: 67.5 years Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/718513	Disc. AE: Loss of energy, Fatigue... AEs leading to discontinuation/dose reduction: Loss of energy (2 patients) Fatigue (2 patients) Lethargy (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/718513
50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Co-administed with:: aspirin(high concentration) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	Disc. AE: Anorexia, Tachypnea... AEs leading to discontinuation/dose reduction: Anorexia Tachypnea Lethargy Coma Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings

AEs

AE	Significance	Dose	Population
Fatigue	2 patients Disc. AE	100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/718513	unhealthy, 67.5 years n = 24 Health Status: unhealthy Condition: Glaucoma Age Group: 67.5 years Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/718513
Lethargy	2 patients Disc. AE	100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/718513	unhealthy, 67.5 years n = 24 Health Status: unhealthy Condition: Glaucoma Age Group: 67.5 years Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/718513
Loss of energy	2 patients Disc. AE	100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/718513	unhealthy, 67.5 years n = 24 Health Status: unhealthy Condition: Glaucoma Age Group: 67.5 years Sex: M+F Population Size: 24 Sources: https://pubmed.ncbi.nlm.nih.gov/718513
Anorexia	Disc. AE	50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Co-administed with:: aspirin(high concentration) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings
Coma	Disc. AE	50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Co-administed with:: aspirin(high concentration) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings
Lethargy	Disc. AE	50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Co-administed with:: aspirin(high concentration) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings
Tachypnea	Disc. AE	50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Co-administed with:: aspirin(high concentration) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2J2 56

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2J2 56	substrate 3326 Sources: https://dmd.aspetjournals.org/content/38/2/347 Page: 348.0	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY560176	https://www.001chemical.com/chem/554-57-4
3B Scientific (Wuhan) Corp	3B1-00324	http://www.3bsc.com/index/pro_info.php?id=20536
3B Scientific (Wuhan) Corp	3B2-5425	http://www.3bsc.com/index/pro_info.php?id=85227
AA Blocks	AA00DENM	http://www.aablocks.com/goods/Goods/detail?id=AA00DENM
AHH Chemical co.,ltd	MT-53566	http://www.ahhchemical.com/product/MT-53566.html
AK Scientific, Inc. (AKSCI)	H773	http://www.aksci.com/item_detail.php?cat=H773
Aaron Chemicals	AR00DFFE	http://www.aaronchem.com/554-57-4
AbMole Bioscience	M2840	http://www.abmole.com/products/methazolamide.html
Achemtek	0104-019526	http://www.achemtek.com/554-57-4
Alfa Chemistry	AP554574-A	https://reagents.alfa-chemistry.com/product/methazolamide-cas-554-57-4-13061.html
Alfa Chemistry	AP554574-B	https://reagents.alfa-chemistry.com/product/methazolamide-cas-554-57-4-13062.html
Ambeed	A120295	https://www.ambeed.com/products/554-57-4.html
Ambinter	Amb17938206	http://www.ambinter.com/reference/17938206
Ambinter	Amb20243176	http://www.ambinter.com/reference/20243176
Ambinter	Amb20665658	http://www.ambinter.com/reference/20665658
Ambinter	Amb21935015	http://www.ambinter.com/reference/21935015
Ambinter	Amb22352755	http://www.ambinter.com/reference/22352755
Angel Pharmatech	AG147138	http://www.angelpharmatech.com/554-57-4.html
Angene	AGN-PC-0SJ4UC	http://www.angenechemical.com/productshow/AGN-PC-0SJ4UC.html
ApexBio Technology	A4364	http://www.apexbt.com/methazolamide.html
Ark Pharm	AK163546	http://www.arkpharminc.com/products/554-57-4.html
Aurora Fine Chemicals LLC	A17.909.366	http://online.aurorafinechemicals.com/info?ID=A17.909.366
Aurum Pharmatech LLC	K-9905	http://www.Aurumpharmatech.com/Product/ProductDetails/K_9905
BLD Pharm	BD137689	http://www.bldpharm.com/products/554-57-4.html
BOC Sciences	554-57-4	https://www.bocsci.com/methazolamide-cas-554-57-4-item-84-71480.html
BioCrick	BCC2318	http://www.biocrick.com/Methazolamide-BCC2318.html
CSNpharm	CSN11393	https://www.csnpharm.com/products/methazolamide.html
Chem Scene	CS-2658	http://www.chemscene.com/554-57-4.html
ChemMol	49427793	http://www.chemmol.com/chemmol/49427793.html
Chemspace	CSSB00015223641	https://chem-space.com/CSSB00015223641
Chemspace	CSSB00016254742	https://chem-space.com/CSSB00016254742
Chemspace	CSSB00016286996	https://chem-space.com/CSSB00016286996
Clearsynth	CS-O-11690	https://www.clearsynth.com/en/CSO11690.html
Combi-Blocks	QA-3504	http://www.combi-blocks.com/cgi-bin/find.cgi?QA-3504
DC Chemicals	DC31747	http://www.dcchemicals.com//product_show-Methazolamide.html
Debye Scientific	DB-052736	http://www.debyesci.com/cas_554-57-4.html
EMD Millipore	215902	http://www.emdbiosciences.com/product/215902
Hairui	HR23832	http://www.hairuichem.com/en/product/554-57-4.html
LGC Standards	DRE-C14999900	https://www.lgcstandards.com/US/en/p/DRE-C14999900
Lab Network	LN00237894	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00237894
MedChem Express	HY-B0553	https://www.medchemexpress.com/methazolamide.html
MolPort	MolPort-001-791-152	https://www.molport.com/shop/molecule-link/MolPort-001-791-152
MolPort	MolPort-019-998-640	https://www.molport.com/shop/molecule-link/MolPort-019-998-640
Molcore	MC560176	https://www.molcore.com/product/554-57-4
MuseChem	I013868	https://www.musechem.com/product/I013868.html
OChem	12480	http://www.ocheminc.com/index.php?act=psearch&pid=554M574
Oakwood	181321	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=162059&ExtHyperLink=1
Sigma-Aldrich	37011_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/37011?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	SML0720_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/sml0720?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1406005_USP	https://www.sigmaaldrich.com/catalog/product/usp/1406005?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S535104	http://www.smolecule.com/products/s535104
Smolecule	S793311	https://www.smolecule.com/products/s793311
Synblock Inc	SB17307	http://www.synblock.com/product/554-57-4.html
THE BioTek	bt-275134	https://www.thebiotek.com/product/inhibitors/bt-275134
TimTec	ST081366	http://www.echemstore.com/st081366-methazolamide.html
abcr GmbH	AB509196	http://www.abcr.com/shop/en/AB509196
eNovation Chemicals	D630718	https://www.enovationchem.com/ProductDetails.asp?ProductID=D630718
eNovation Chemicals	K35405	https://www.enovationchem.com/ProductDetails.asp?ProductID=K35405
iChemical	EBD27355	http://www.ichemical.com/products/554-57-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-1665001985	https://mcule.com/MCULE-1665001985/

PubMed

Title	Date	PubMed
Urinary calculus during methazolamide therapy.	1976 May	1275042
Inhibition of aquaporin-mediated CO2 diffusion and voltage-gated H+ channels by zinc does not alter rabbit lung CO2 and NO excretion.	2002 Dec	12444909
Forskolin-induced clearance of the fluorescent dye sulforhodamine from rat parotid intralobular duct lumen: visualization of the secretory function under a confocal laser scanning microscope.	2002 Dec 1	12533784
Carbachol-induced fluid movement through methazolamide-sensitive bicarbonate production in rat parotid intralobular ducts: quantitative analysis of fluorescence images using fluorescent dye sulforhodamine under a confocal laser scanning microscope.	2002 Sep	12416726
Benefits and risks of pharmacological treatments for essential tremor.	2003	12735785
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the perfluorobenzoyl analogue of methazolamide. Implications for the drug design of fluorinated inhibitors.	2003 Aug	14567544
Focal CO2/H+ alters phrenic motor output response to chemical stimulation of cat pre-Botzinger complex in vivo.	2003 Jun	12611760
Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats.	2004 Apr	14766795
Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties.	2004 Dec 6	15501040
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.	2004 Feb 26	14971907
NHE3 inhibition activates duodenal bicarbonate secretion in the rat.	2004 Jan	12881227
Low-dose PGE2 mimics the duodenal secretory response to luminal acid in mice.	2004 Jun	14764447
Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides.	2004 Jun 21	15149691
Acid-base effects on intestinal Cl- absorption and vesicular trafficking.	2004 May	15075205
Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitro.	2005 Apr 11	15778055
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.	2005 Feb 15	15686931
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.	2005 Feb 15	15686895
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?	2005 Feb 15	15686894
Stimulation of renal sulfate secretion by metabolic acidosis requires Na+/H+ exchange induction and carbonic anhydrase.	2005 Jul	15741604
Rat adrenal chromaffin cells are neonatal CO2 sensors.	2005 Jul 13	16014724
Functional interaction of carbonic anhydrase and chloride/bicarbonate exchange in human platelets.	2005 Nov	16236600
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.	2005 Nov 1	16165351
Carbonic anhydrase in the adult mosquito midgut.	2005 Sep	16109888
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.	2005 Sep 1	16039848
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.	2006 Apr 15	16459077
Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.	2006 Jan	16368240
[Diuretic therapy in heart failure].	2006 Jan-Feb	16634001
Degradation and effects of the potential mosquito larvicides methazolamide and acetazolamide in sheepshead minnow (Cyprinodon variegatus).	2006 Jul	16054216
The carbonic anhydrase inhibitors methazolamide and acetazolamide have different effects on the hypoxic ventilatory response in the anaesthetized cat.	2006 Jul 15	16675491
Epithelial carbonic anhydrases facilitate PCO2 and pH regulation in rat duodenal mucosa.	2006 Jun 15	16556652
Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study.	2006 Mar	19412450
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.	2006 Mar 23	16539401
Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds.	2006 Oct	16858005
The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents.	2007	17504129
Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition.	2007 Apr	17209136
Statement on high-altitude illnesses. An Advisory Committee Statement (ACS).	2007 Apr 1	17520777
Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy.	2007 Feb 15	17124262
CO2 chemosensing in rat oesophagus.	2008 Dec	18682519
Carbonic anhydrase II and alveolar fluid reabsorption during hypercapnia.	2008 Jan	17690328
Pharmacological impact on loop gain properties to prevent irregular breathing.	2008 Mar	18441386
Recent advances in pharmacotherapy of glaucoma.	2008 Oct	20040958
Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease.	2008 Sep 17	18799679
QSAR studies for the inhibition of the transmembrane carbonic anhydrase isozyme XIV with sulfonamides using PRECLAV software.	2009 Apr	18830873
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.	2009 Apr 23	19317447
Functional coupling of the downregulated in adenoma Cl-/base exchanger DRA and the apical Na+/H+ exchangers NHE2 and NHE3.	2009 Feb	19056765
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.	2009 Feb 1	19124253
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.	2009 Jul 15	19520577
Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury.	2009 May	19299628
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.	2009 May 14	19338333
Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy.	2009 Nov 1	19648295

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Glaucoma 50 to 100 mg orally 2 or 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Methazolamide (0.1 mM) inhibited acid-induced [CO(2)](t) increase in mice.

Name

Type

Language

METHAZOLAMIDE

Official Name

English

METHAZOLAMIDE [HSDB]

Common Name

English

methazolamide [INN]

Common Name

English

ACETAMIDE, N-(5-(AMINOSULFONYL)-3-METHYL-1,3,4-THIADIAZOL-2(3H)-YLIDENE)-

Systematic Name

English

METHAZOLAMIDE [VANDF]

Common Name

English

METHAZOLAMIDE [USP-RS]

Common Name

English

NEPTAZANE

Brand Name

English

Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-, [N(E)]-

Systematic Name

English

N-(4-METHYL-2-SULFAMOYL-.DELTA.(SUP 2)-1,3,4-THIADIAZOLIN-5-YLIDENE)ACETAMIDE

Common Name

English

METHAZOLAMIDE [JAN]

Common Name

English

Methazolamide [WHO-DD]

Common Name

English

VVP808

Code

English

METHAZOLAMIDE [MI]

Common Name

English

NEPTAZANEAT

Common Name

English

METHAZOLAMIDE [USP MONOGRAPH]

Common Name

English

NSC-758426

Code

English

[N(E)]-N-[5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide

Systematic Name

English

METHENAMIDE

Common Name

English

VVP-808

Code

English

L-584601

Code

English

METHAZOLAMIDE [MART.]

Common Name

English

METHAZOLAMIDE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

LIVERTOX

NBK548664